hero image

Biogen to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 17, 2018 Investor Relations

Cambridge, MA, - - Biogen Inc.  (NASDAQ: BIIB) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 7, 2019 at 3:30 p.m. PST, 6:30 p.m. EST. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors.  An archived version of the webcast will be available following the presentation.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

 

Contact:

Karen Jewell

Investor Relations

Biogen

781.464.2442

thumb
July 23, 2021
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), which will be held in

thumb
July 22, 2021
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

NOTE: ADUHELM TM (aducanumab-avwa) injection 100 mg/mL solution is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical